The drug, designed by biotech company Aimmune Therapeutics Inc., is an oral immunotherapy indicated for the mitigation of allergic reactions, that may occur with accidental exposure to peanut.
The treatment is approved in patients aged between 4-17 years old with a confirmed diagnosis of peanut allergy.
The treatment is approved in patients aged between 4-17 years old with a confirmed diagnosis of peanut allergy.
